Scholarlink

Purpose <p>To evaluate the impact of Janus kinase inhibitors (JAKi) compared to anti-tumor necrosis factor-α antibodies (anti-TNF) on anterior uveitis (AU) risk in patients with autoimmune diseases.</p> Methods <p>This retrospective cohort study analyzed deidentified global electronic medical records from December 2011 to December 2023, with 2-year follow-up. Adults with ankylosing spondylitis, psoriasis, psoriatic arthritis, or inflammatory bowel disease newly prescribed JAKi or anti-TNF were included. After 1:1 propensity score matching, 3,332 matched pairs were analyzed. AU incidence was assessed using Kaplan-Meier analysis.</p> Results <p>JAKi was associated with lower AU risk compared to total anti-TNF (HR: 0.43, 95% CI: 0.20–0.92) and non-monoclonal anti-TNF (HR: 0.28, 95% CI: 0.11–0.68). In ankylosing spondylitis, JAKi showed lower risk versus all anti-TNF biologics: total (HR: 0.30, 95% CI: 0.10–0.91), non-monoclonal (HR: 0.33, 95% CI: 0.11–0.99), and monoclonal anti-TNF (HR: 0.26, 95% CI: 0.09–0.78).</p> Conclusions <p>JAKi use is associated with reduced AU incidence compared to anti-TNF therapies, particularly in ankylosing spondylitis, supporting JAKi as a potential treatment option for autoimmune-related uveitis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Janus Kinase inhibitors associated with reduced anterior uveitis risk in autoimmune diseases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月10日

查看全文
  • Shiao-Ling Wu,
  • Ssu-Yu Pan,
  • Chien-Hsiang Weng,
  • Jun-Fu Lin,
  • Yun Hsia,
  • Mey-Fann Lee,
  • Yu-Wen Chu,
  • Wei-Ting Ho,
  • Shun-Ping Huang,
  • De-Xian Li,
  • Hui-Ju Lin,
  • I-Jong Wang,
  • Yi-Ming Chen,
  • Chien-Chih Chou

摘要

Purpose

To evaluate the impact of Janus kinase inhibitors (JAKi) compared to anti-tumor necrosis factor-α antibodies (anti-TNF) on anterior uveitis (AU) risk in patients with autoimmune diseases.

Methods

This retrospective cohort study analyzed deidentified global electronic medical records from December 2011 to December 2023, with 2-year follow-up. Adults with ankylosing spondylitis, psoriasis, psoriatic arthritis, or inflammatory bowel disease newly prescribed JAKi or anti-TNF were included. After 1:1 propensity score matching, 3,332 matched pairs were analyzed. AU incidence was assessed using Kaplan-Meier analysis.

Results

JAKi was associated with lower AU risk compared to total anti-TNF (HR: 0.43, 95% CI: 0.20–0.92) and non-monoclonal anti-TNF (HR: 0.28, 95% CI: 0.11–0.68). In ankylosing spondylitis, JAKi showed lower risk versus all anti-TNF biologics: total (HR: 0.30, 95% CI: 0.10–0.91), non-monoclonal (HR: 0.33, 95% CI: 0.11–0.99), and monoclonal anti-TNF (HR: 0.26, 95% CI: 0.09–0.78).

Conclusions

JAKi use is associated with reduced AU incidence compared to anti-TNF therapies, particularly in ankylosing spondylitis, supporting JAKi as a potential treatment option for autoimmune-related uveitis.